← Back to Search

Omega-3 Fatty Acid

DHA for Autism

N/A
Waitlist Available
Led By Sherie Novotny, MD
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three years
Awards & highlights

Summary

This trialtests if DHA, a component of fish oil, can help reduce symptoms of autism in children and adolescents.

Who is the study for?
This trial is for children and adolescents aged 5-17 with Autism Spectrum Disorder. Participants must meet specific autism diagnostic criteria, be seizure-free for at least 6 months if applicable, and capable of giving consent through a guardian. Sexually active females must use birth control. Those with certain medical conditions or on recent psychoactive medications are excluded.
What is being tested?
The study tests the effects of Docosahexanoic Acid (DHA), an omega-3 fatty acid found in fish oil, against a placebo over 12 weeks to see if it improves symptoms of autism. It also examines genetic factors related to DHA and its biomarkers in urine.
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects may include typical reactions associated with omega-3 supplements such as fishy aftertaste, gastrointestinal discomfort or disturbances, and allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three years
This trial's timeline: 3 weeks for screening, Varies for treatment, and three years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Amelioration of phenotypic features of autism
Secondary study objectives
oxidative stress biomarkers

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Docosa Hexanoic AcidActive Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
440 Previous Clinical Trials
65,250 Total Patients Enrolled
10 Trials studying Autism Spectrum Disorder
177 Patients Enrolled for Autism Spectrum Disorder
Sherie Novotny, MDPrincipal InvestigatorRutgers-RWJMS
1 Previous Clinical Trials
20 Total Patients Enrolled
~9 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top